Dr. Bernard Fox honored for his lifetime contributions to cancer research

July 31, 2024 Providence inScope Content Team

PROVIDENCE CANCER INSTITUTE – Bernard A. Fox, Ph.D., has been honored with the 2024 Society of Immunotherapy of Cancer Lifetime Achievement Award.

Dr. Fox is the Harder Family Endowed Chair for Cancer Research and leader of the Laboratory of Molecular and Tumor Immunology, Earle A. Chiles Research Institute, a division of Providence Cancer Institute of Oregon.

His lifelong commitment to advancing cancer research and education includes key milestones.

His many contributions at Earle A. Chiles Research Institute have included professional and academic engagements that have helped elevate the field of immunotherapy research.
He led the formation of the World Immunotherapy Council and currently serves as chair, bringing together scientists and fellows worldwide to advance scientific knowledge and collaboration.
A sought-after lecturer and advisor, Dr. Fox has held faculty and committee positions at universities and philanthropic organizations across the U.S., Europe and Asia, including the National Institutes of Health and the Food and Drug Administration.
In his longtime service to the Society of Immunotherapy of Cancer, Dr. Fox has served as a president and ambassador. He received the 2015 Visionary/Legacy Award, 2020 Team Science Award and the 2022 Tara Withington Public Service Award for fostering and enhancing the field of cancer immunotherapy through increasing public understanding, awareness and research efforts.
Also in 2020, he was honored with the Onlus Bridge Award by the Melanoma Foundation for outstanding and lifelong contributions to melanoma research.

“Working alongside Dr. Fox for over three decades has been nothing short of inspiring. His relentless dedication to advancing cancer research and immunotherapy has helped shape the field. His groundbreaking work and visionary leadership at Earle A. Chiles Research Institute are a testament to his commitment to finding innovative solutions to treating cancer. Beyond his remarkable professional achievements, Dr. Fox is an excellent colleague and a friend whose passion and integrity set a standard for us all,” says Walter Urba, M.D., Ph.D., chief medical officer, Providence Cancer Institute of Oregon, and director of cancer research, Earle A. Chiles Research Institute.

About the Author

The inScope content team focuses on bringing you the latest in clinical news from our team of world-class medical providers and physician leaders.
More Content by Providence inScope Content Team

Welcome to your journey for creating a healthier you

Dr. Bernard Fox honored for his lifetime contributions to cancer research

About the Author

Previous Article

Next Article

Dr. Bernard Fox honored for his lifetime contributions to cancer research

About the Author

Previous Article

Next Article

Most Recent Articles

The Gamma Knife Esprit stereotactic radiosurgery system moves beyond a fixed headframe to target the most challenging areas of the brain with exceptional accuracy.

Thousands upon thousands of cancer patients and family members at Providence have benefited from the life-changing work of Dr. Walter Urba. Learn about his remarkable career.

What is required to make clinical trials accessible to people in Hood River and other Columbia Gorge communities? Learn more about why it's important to expand access to studies and cancer care.

A joint study between Providence, Microsoft and the University of Washington detailing work to create a novel AI-powered pathology model that will lay the foundation to improve patient outcomes.

Years after the start of the pandemic, more than 200 patients continue to be cared for at Providence for ongoing symptoms that remain from contracting COVID-19. Learn how Providence continues helping.

A new investigator-initiated study for patients with metastatic melanoma and HNSCC aims to evaluate a galectin-3 inhibitor as a way to “remove the brakes” from the immune system.

The advent of MRI scanning of the brain and spinal cord was a giant leap forward in improving the ability to diagnose multiple sclerosis with greater sensitivity and reliability.

Growing the surgical oncology programs at Providence Cancer Institute is a testament to our commitment to providing research-focused, comprehensive services and improving outcomes for patients.

During winter months when the days are shorter and darker, both postpartum depression and baby blues may be more difficult.

A study led by Dr. Christopher Darus may offer hope to women with persistent endometrial cancer. Currently, the prognosis is poor for women with this form of cancer.

Providence researchers say comprehensive genomic profiling can be pivotal in identifying gene mutations in a patient and tailoring personalized treatment strategies.

Being able to assess the level of fibrosis and make appropriate referrals is important in the care of patients with Steatotic Liver Disease (formerly known as Fatty Liver).

The regional pharmacy team regularly updates its Pathway to Treat tool for providers, helping to guide evidence-based care.